Lysosomal Storage Diseases Therapeutics Market
According to Intent Market Research, the Lysosomal Storage Diseases Therapeutics Market is expected to grow from USD 9.7 Billion in 2024-e at a CAGR of 9.8% to touch USD 16.9 Billion by 2030. The Lysosomal Storage Diseases Therapeutics Market is dominated by key players such as, Sanofi S.A., Takeda Pharmaceutical Company Limited, BioMarin Pharmaceutical Inc., Pfizer Inc., Amicus Therapeutics, Inc., and Alexion Pharmaceuticals, Inc.